Pictor, an Auckland, New Zealand-based immunodiagnostics company, raised $5M in funding.
The backers were not disclosed.
The company intends to use the funds to accelerate pipeline product development projects along with market development activities within Australia/New Zealand, the US and Europe for its Human Health and Animal Health portfolios.
Led by CEO Tadd Lazarus and Chief Medical Officer Tadd Lazarus, MD, Pictor is an in vitro diagnostics company that offers a patented multiplexed platform for testing of complex and infectious diseases for human and animal health. Its PictArray multiplexed technology makes it possible to test multiple disease markers in a single test simultaneously. The company’s lead product, the PictArray SARS-CoV-2 IgG ELISA Kit, enables informed clinical intervention to manage the threat of COVID-19.
FinSMEs
05/12/2022